
The introduction of the new $2,000 US tax reporting threshold in January 2026 marked an important change for clinical trial patient payments. As sponsors, CROs and research sites approach the end of the first tax year under these updated requirements, understanding the implications for patient stipends, reimbursements and reporting obligations is increasingly important.
Financial considerations can play a significant role in a patient’s decision to participate in a clinical trial. Travel expenses, time away from work, childcare arrangements and other costs can create financial pressure for patients and their families. While stipends and reimbursements can help reduce these burdens, uncertainty around how clinical trial payments are taxed can introduce additional concerns.
Although the increased reporting threshold may reduce administrative requirements, it does not change whether payments are taxable. For sponsors, CROs and research sites, understanding this distinction is essential when designing patient payment programs that support participation without creating unnecessary financial uncertainty.
What has changed for clinical trial patient payments in 2026?
Under the One Big Beautiful Bill Act, the Internal Revenue Service (IRS) increased the reporting threshold for certain payments reported on Form 1099-MISC from $600 to $2,000, effective for payments made from January 1, 2026.
This means organizations making qualifying payments generally only need to issue Form 1099-MISC when payments to an individual reach $2,000 during the calendar year, subject to applicable reporting rules and exceptions.
The threshold will also be adjusted for inflation from 2027.
For clinical trials, this change is particularly relevant to patient stipends and other forms of compensation that may be classified as reportable income.
However, the increase in the reporting threshold does not mean patients can receive up to $2,000 tax-free.
The distinction between tax reporting and tax liability remains important.
Are clinical trial stipends taxable?
In the US, payments made to patients for participating in clinical research, including certain stipends and honoraria, are generally considered taxable income.
Although the reporting threshold has increased, patients may still have an obligation to report taxable income, even when they do not receive a Form 1099-MISC.
For example, a patient receiving $1,500 in qualifying stipends during 2026 may no longer trigger the standard Form 1099-MISC reporting requirement. However, those payments may still be subject to income tax depending on the patient’s individual circumstances.
It’s also important to distinguish between different types of patient payments.
Patient stipends: Payments intended to compensate patients for their time, inconvenience or participation are generally treated as taxable income.
Expense reimbursements: Payments covering qualifying expenses incurred during trial participation, such as travel or accommodation, may receive different tax treatment depending on how they are structured and documented.
These distinctions matter because patients may receive both types of payments throughout a study.
Clear communication about the purpose and treatment of payments can help patients understand their financial arrangements and make informed decisions.
Why financial uncertainty remains a barrier to clinical trial participation
Although the increased reporting threshold represents a change in administrative requirements, it does not eliminate the financial challenges patients may experience when participating in research.
For many patients, the cost of participation extends beyond the clinical trial itself.
Attending site visits may involve transportation costs, overnight accommodation, childcare arrangements or time away from paid employment. Patients managing ongoing health conditions may already be facing financial pressures before considering participation.
Additional uncertainty around stipends, reimbursements and potential tax obligations can make these decisions more difficult.
For patients receiving means-tested government benefits, the situation may be particularly complex. Depending on the benefit program and individual circumstances, certain clinical trial payments may be considered when assessing income or eligibility. Patients should be encouraged to seek appropriate guidance to understand how receiving payments could affect their benefits.
When patients are uncertain about the financial implications of participation, they may hesitate to enroll, decline payments or face additional challenges remaining in a study.
Reducing financial barriers is therefore about more than providing payments. It’s about ensuring patients can participate without taking on unnecessary financial burden or uncertainty.
What should sponsors and CROs consider?
The updated reporting threshold provides an opportunity for sponsors and CROs to review how patient payments are planned, communicated and administered.
Several considerations can help create a more patient-centered approach.
1. Communicate payment arrangements clearly
Patients should understand what payments they may receive, when they can expect them and whether different payments are classified as stipends or expense reimbursements.
Providing clear information early in the trial journey can help patients anticipate potential financial implications and identify questions requiring professional tax advice.
2. Minimize out-of-pocket expenses
Even when expenses are reimbursed, patients may still need to pay for transportation, accommodation or other costs upfront.
For some patients, waiting for reimbursement can create financial strain.
Where appropriate, arranging and paying for travel directly, or providing suitable payment solutions, can help reduce the need for patients to cover significant costs themselves.
3. Make payments timely and accessible
Delays in receiving payments can create additional challenges, particularly for patients attending frequent appointments or traveling long distances.
Reliable payment processes and clear expectations can help reduce uncertainty and make participation more manageable.
4. Consider individual patient circumstances
Financial circumstances vary considerably between patients.
Some may need assistance arranging travel, while others may have concerns about how payments could affect their income or benefits.
Recognizing these differences and providing appropriate support can help make clinical trials more accessible to a wider patient population.
5. Review reporting and compliance requirements
The new threshold is an important consideration for payment administration, but sponsors and CROs should continue to assess applicable tax reporting obligations, payment classifications and documentation requirements.
For multinational studies, these considerations become more complex, with different tax and reporting requirements across countries.
Supporting patients beyond the payment
At mdgroup, we believe patients should be able to focus on their health and participation in clinical research, rather than worrying about the practical and financial challenges involved.
Our Patient Payments service helps sponsors, CROs and research sites manage patient stipends and expense reimbursements, supporting a more straightforward payment experience throughout the clinical trial journey.
Combined with our Patient Travel and Patient Coordination services, we help address many of the practical barriers that can make participation difficult.
From arranging travel and accommodation to coordinating support and managing payments, our services are designed to make clinical research work around patients’ lives.
This integrated approach can help reduce administrative pressure on research sites while supporting patient engagement and retention.
Making clinical trial participation more accessible
The increase in the US reporting threshold from $600 to $2,000 is a notable development for clinical trial payment administration.
However, the wider challenge remains unchanged.
Patients should not face unnecessary financial obstacles when contributing to clinical research.
For sponsors, CROs and research sites, clear communication, thoughtful payment planning and practical patient support can make a meaningful difference.
By considering the full financial experience of participation, the industry can help create clinical trials that are more accessible, manageable and supportive of patients’
At mdgroup, we help sponsors, CROs and research sites reduce the practical and financial barriers to clinical trial participation through personalized patient support.
Looking to simplify patient payments for your next clinical trial?
Discover how our Patient Payments services can help deliver a more straightforward payment experience for patients and research sites.
Disclaimer: This article is intended for general informational purposes only and does not constitute tax or legal advice. Tax treatment and reporting obligations may vary depending on individual circumstances and applicable regulations.









